Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 260 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Syncytial Virus (RSV) Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

NCT03529773
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Formulation A, Formulation B, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
40
States / cities
Mobile, Alabama • Anaheim, California • La Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 5, 2026, 10:21 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

NCT05229068
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Missoula, Montana • Norfolk, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 5, 2026, 10:21 AM EDT
Recruiting Phase 2 Interventional

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

NCT07214571
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
S-337395, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Los Angeles, California • Modesto, California • Toluca Lake, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

NCT05886777
View directory record Official record
Conditions
Healthy Participants
Interventions
Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
1,142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
37
States / cities
Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 5, 2026, 10:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers

NCT05964582
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 21 Months
Enrollment
344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Omaha, Nebraska • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

NCT01290419
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV-F Particle Vaccine, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 5, 2026, 10:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children

NCT00593918
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 24 Months
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 5, 2026, 10:21 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

NCT03656510
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
28 Days to 3 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Madera, California • Ventura, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

NCT03636906
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine, Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine, GSK's pneumococcal polysaccharide conjugate vaccine, GSK's meningococcal group A, C, W-135 and Y conjugate vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 7 Months
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

NCT00496821
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2007 · Synced Oct 5, 2026, 10:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)

NCT05765396
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection, COVID-19 ARDS, Corona Virus Infection, Influenza, RSV Infection
Interventions
imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 5, 2026, 10:21 AM EDT
Completed No phase listed Observational

Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer

NCT02067286
View directory record Official record
Conditions
Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
Interventions
Not listed
Lead sponsor
IQuum, Inc.
Industry
Eligibility
Not listed
Enrollment
1,642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Delray Beach, Florida • Savannah, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

NCT02608502
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV-F Vaccine, Phosphate Buffer Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
11,850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
60
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

RSV F Dose-Ranging Study in Women

NCT01960686
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Low dose RSV F Antigen, High dose RSV F Antigen, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
Walnut Creek, California • Stockbridge, Georgia • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

NCT00767416
View directory record Official record
Conditions
Healthy
Interventions
MEDI-559, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Month to 23 Months
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
75
States / cities
Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

NCT04227210
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV vaccine MV-012-968 (dosage #1), RSV vaccine MV-012-968 (dosage #2)
Biological
Lead sponsor
Meissa Vaccines, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 5, 2026, 10:21 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

MVA-BN-RSV Vaccine Trial

NCT05238025
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA-BN-RSV vaccine, Tris Buffered Saline (TBS)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
60 Years and older
Enrollment
20,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
105
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate EDP 938 Regimens in Children With RSV

NCT04816721
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
28 Days to 36 Months
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 5, 2026, 10:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate MEDI-534 in Healthy Adults

NCT00111878
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections, Parainfluenza Infections
Interventions
MEDI-534
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
3
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2007 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557

NCT00578682
View directory record Official record
Conditions
Healthy
Interventions
MEDI-557
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 5, 2026, 10:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

NCT04933968
View directory record Official record
Conditions
Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
Interventions
ALVR106, Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
17 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

NCT03755778
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Itraconazole, Rifampin, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

NCT02952339
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID ΔM2-2 1030s vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 5, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-323 in Healthy Subjects

NCT05587478
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-323, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 5, 2026, 10:21 AM EDT